Developer docs
API playgroundTry for free, no card

Search company profiles

Angitia Biopharmaceuticals

Full company profile

uuid0000i9r

Namestring
Angitia Biopharmaceuticals
Legal namestring
Angitia Biopharmaceuticals Limited
Websiteurl
angitiabio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing bispecific antibody therapeutics for serious musculoskeletal diseases. Founded in 2018 and headquartered in Woodland Hills, California, with additional operations in China, the company is advancing three drug candidates through clinical development: AGA2118 for postmenopausal osteoporosis (Phase 2 ARTEMIS trial with 379 women enrolled and topline expected in 2027), AGA2115 for osteogenesis imperfecta (Phase 2 IDUN trial, first patient dosed January 2026), and AGA111 for spinal fusion. The company's core technology centers on bispecific antibodies that simultaneously engage sclerostin and Dickkopf-1 (DKK1) proteins, a dual-target architecture positioned to overcome the limitations of single-target therapies such as Amgen's romosozumab. Its website also highlights adjacent musculoskeletal indications including bone metastasis, muscle disorders, and osteoarthritis.

The company is pre-revenue and finances operations entirely through venture capital. Across six disclosed funding rounds since 2020, Angitia has raised approximately $406 million in aggregate, most recently a $130 million Series D in February 2026 co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners, with participation from Bain Capital Life Sciences, Hillhouse, OrbiMed, BlackRock, Wellington Management, RA Capital, and others. A $120 million Series C led by Bain Capital Life Sciences closed in December 2024, following a $46 million Series B led by Morningside in October 2023.

Angitia intends to commercialize its biologic products through traditional pharmaceutical distribution channels — hospital pharmacies, specialty pharmacies, and healthcare providers — upon regulatory approval, targeting postmenopausal women with osteoporosis, osteogenesis imperfecta patients, and patients requiring spinal fusion procedures. The company employs 51–100 staff, is led by founder and CEO Hua Zhu Ke, and added Kevin Li, M.D., Partner at Frazier Life Sciences, to its Board of Directors in connection with the Series D financing.

Short descriptiontext

Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing bispecific antibody therapeutics that simultaneously target sclerostin and DKK1 proteins for serious musculoskeletal diseases, including osteoporosis, osteogenesis imperfecta, and spinal fusion indications.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWestlake Village, United States
HQ citystring
Westlake Village
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
musculoskeletal therapeutics, bispecific antibodies, bone disease biologics, osteoporosis treatment, osteogenesis imperfecta therapy
Industry1 code
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Musculoskeletal Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Biopharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage company. Revenue expected from sales of approved biologic therapeutics for musculoskeletal diseases including osteoporosis, osteogenesis imperfecta, and spinal fusion upon successful clinical development and regulatory approval.

longevity.technology
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Angitia Biopharmaceuticals is a clinical-stage biotechnology company that discovers and develops biologic therapeutic candidates for serious musculoskeletal diseases. Its pipeline comprises three bispecific antibody drug candidates: AGA2118 for postmenopausal osteoporosis (Phase 2 ARTEMIS trial), AGA2115 for osteogenesis imperfecta (Phase 2 IDUN trial), and AGA111 for spinal fusion. The bispecific antibodies simultaneously target sclerostin and Dickkopf-1 (DKK1) proteins to overcome limitations of single-target bone therapies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Phase 2 trial ARTEMIS enrolled 379 women for AGA2118 in postmenopausal osteoporosis - topline results expected 2027
Product overview1 text field

Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing a pipeline of bispecific antibody drug candidates for serious musculoskeletal diseases. The company's portfolio includes three clinical-stage candidates: AGA2118 for postmenopausal osteoporosis, AGA2115 for osteogenesis imperfecta, and AGA111 for spinal fusion. The bispecific antibodies target both sclerostin and Dickkopf-1 (DKK1) proteins simultaneously to overcome limitations of single-target therapies for bone loss conditions.

Product and service3 records
1AGA2118
CategoryBiologic drug candidate
Description

Bispecific antibody drug candidate targeting sclerostin and Dickkopf-1 (DKK1) proteins simultaneously, in development for the treatment of postmenopausal osteoporosis. Currently in Phase 2 (ARTEMIS) trial with enrollment of 379 women completed.

2AGA2115
CategoryBiologic drug candidate
Description

Bispecific antibody drug candidate in development for the treatment of osteogenesis imperfecta (OI), a serious genetic bone disorder. Currently in Phase 2 (IDUN) trial with first participant dosed in January 2026.

3AGA111
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

UCB is Amgen's co-development and co-promotion partner on romosozumab (Evenity) for osteoporosis. UCB represents a potential strategic acquirer or commercial partner for Angitia given overlapping bone-disease commercial infrastructure outside the US.

TypeBroad incumbent
Description

Amgen co-developed and markets Evenity (romosozumab), the first approved sclerostin-targeting antibody for postmenopausal osteoporosis. Romosozumab is the most direct competitive analog to Angitia's AGA2118 in mechanism and indication, though it targets only one of the two pathways AGA2118 engages.

TypeOthers
Description

Genmab is a leader in bispecific antibody engineering with its DuoBody platform, used across multiple therapeutic areas. While not a direct competitor in musculoskeletal disease, Genmab is a technology-platform peer whose valuation and partnership economics inform the bispecific antibody space Angitia operates in.

TypeBroad incumbent
Description

Lilly markets Forteo (teriparatide) and Taltz in adjacent bone and inflammation indications, and is one of the dominant incumbent players in metabolic bone disease. Lilly represents the broad incumbent peer and potential strategic acquirer given the size of its bone franchise.

TypeEmerging player
Description

Ascendis Pharma develops TransCon PTH (palopegteriparatide) for hypoparathyroidism and is exploring bone-related indications using its TransCon prodrug technology. The company is a peer in late-stage bone therapeutics with a similar clinical-stage, partnership-friendly profile.

TypeEmerging player
Description

Entera Bio is developing oral PTH formulations (EB613) for osteoporosis and hypoparathyroidism. While mechanistically distinct from Angitia's bispecific antibodies, Entera is a clinical-stage peer targeting the same postmenopausal osteoporosis market with a differentiated route of administration.

TypeBroad incumbent
Description

BridgeBio is a clinical-stage rare disease biotech with multiple programs across genetic diseases. While not focused on musculoskeletal indications, BridgeBio is a structural peer in the clinical-stage rare disease and orphan drug space, particularly relevant for valuing Angitia's AGA2115 osteogenesis imperfecta program.

TypeDirect peer
Description

Mereo is advancing setrusumab (anti-sclerostin) for osteogenesis imperfecta and other bone disorders, making it a direct competitor to Angitia's AGA2115 in the OI indication. Both companies are clinical-stage with a shared target biology in rare bone disease.

TypeDirect peer
Description

Ultragenyx is developing UX143 (setrusumab), an anti-sclerostin antibody for osteogenesis imperfecta — directly competing with Angitia's AGA2115 in the same rare bone disease indication and overlapping mechanism (sclerostin inhibition).

TypeDirect peer
Description

Radius developed and previously marketed Tymlos (abaloparatide), a parathyroid hormone analog for postmenopausal osteoporosis. Radius is a direct commercial-stage peer in osteoporosis therapeutics and a useful comparator for go-to-market economics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors23 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Angitia Biopharmaceuticals

Musculoskeletal Biopharmaceuticalsangitiabio.com

Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing bispecific antibody therapeutics that simultaneously target sclerostin and DKK1 proteins for serious musculoskeletal diseases, including osteoporosis, osteogenesis imperfecta, and spinal fusion indications.

What Angitia Biopharmaceuticals does

Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing bispecific antibody therapeutics for serious musculoskeletal diseases. Founded in 2018 and headquartered in Woodland Hills, California, with additional operations in China, the company is advancing three drug candidates through clinical development: AGA2118 for postmenopausal osteoporosis (Phase 2 ARTEMIS trial with 379 women enrolled and topline expected in 2027), AGA2115 for osteogenesis imperfecta (Phase 2 IDUN trial, first patient dosed January 2026), and AGA111 for spinal fusion. The company's core technology centers on bispecific antibodies that simultaneously engage sclerostin and Dickkopf-1 (DKK1) proteins, a dual-target architecture positioned to overcome the limitations of single-target therapies such as Amgen's romosozumab. Its website also highlights adjacent musculoskeletal indications including bone metastasis, muscle disorders, and osteoarthritis.

The company is pre-revenue and finances operations entirely through venture capital. Across six disclosed funding rounds since 2020, Angitia has raised approximately $406 million in aggregate, most recently a $130 million Series D in February 2026 co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners, with participation from Bain Capital Life Sciences, Hillhouse, OrbiMed, BlackRock, Wellington Management, RA Capital, and others. A $120 million Series C led by Bain Capital Life Sciences closed in December 2024, following a $46 million Series B led by Morningside in October 2023.

Angitia intends to commercialize its biologic products through traditional pharmaceutical distribution channels — hospital pharmacies, specialty pharmacies, and healthcare providers — upon regulatory approval, targeting postmenopausal women with osteoporosis, osteogenesis imperfecta patients, and patients requiring spinal fusion procedures. The company employs 51–100 staff, is led by founder and CEO Hua Zhu Ke, and added Kevin Li, M.D., Partner at Frazier Life Sciences, to its Board of Directors in connection with the Series D financing.

Angitia Biopharmaceuticals firmographics

Firmographics
Name
Angitia Biopharmaceuticals
Legal name
Angitia Biopharmaceuticals Limited
Website
https://angitiabio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
51–100 employees
Short description
Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing bispecific antibody therapeutics that simultaneously target sclerostin and DKK1 proteins for serious musculoskeletal diseases, including osteoporosis, osteogenesis imperfecta, and spinal fusion indications.
Ownership category
akta.pro rank

Angitia Biopharmaceuticals industry classification

Industry
Product category
Musculoskeletal Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Musculoskeletal therapeutics
  • Bispecific antibodies
  • Bone disease biologics
  • Osteoporosis treatment
  • Osteogenesis imperfecta therapy

Where Angitia Biopharmaceuticals is headquartered

Location

Headquarters

HQ city
Westlake Village
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Angitia Biopharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Biopharmaceutical Product Sales: Pre-revenue clinical-stage company. Revenue expected from sales of approved biologic therapeutics for musculoskeletal diseases including osteoporosis, osteogenesis imperfecta, and spinal fusion upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Angitia Biopharmaceuticals product offering

Product offering

Core offering

Angitia Biopharmaceuticals is a clinical-stage biotechnology company that discovers and develops biologic therapeutic candidates for serious musculoskeletal diseases. Its pipeline comprises three bispecific antibody drug candidates: AGA2118 for postmenopausal osteoporosis (Phase 2 ARTEMIS trial), AGA2115 for osteogenesis imperfecta (Phase 2 IDUN trial), and AGA111 for spinal fusion. The bispecific antibodies simultaneously target sclerostin and Dickkopf-1 (DKK1) proteins to overcome limitations of single-target bone therapies.

Product overview

Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing a pipeline of bispecific antibody drug candidates for serious musculoskeletal diseases. The company's portfolio includes three clinical-stage candidates: AGA2118 for postmenopausal osteoporosis, AGA2115 for osteogenesis imperfecta, and AGA111 for spinal fusion. The bispecific antibodies target both sclerostin and Dickkopf-1 (DKK1) proteins simultaneously to overcome limitations of single-target therapies for bone loss conditions.

Differentiator

Problem solved

Functional benefit

Products and services

  • AGA2118 Bispecific antibody drug candidate targeting sclerostin and Dickkopf-1 (DKK1) proteins simultaneously, in development for the treatment of postmenopausal osteoporosis. Currently in Phase 2 (ARTEMIS) trial with enrollment of 379 women completed.
  • AGA2115 Bispecific antibody drug candidate in development for the treatment of osteogenesis imperfecta (OI), a serious genetic bone disorder. Currently in Phase 2 (IDUN) trial with first participant dosed in January 2026.
  • AGA111

Quantifiable outcome

  • Phase 2 trial ARTEMIS enrolled 379 women for AGA2118 in postmenopausal osteoporosis - topline results expected 2027

Companies that use Angitia Biopharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles1 record

Angitia Biopharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Angitia Biopharmaceuticals partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Angitia Biopharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • UCB: UCB is Amgen's co-development and co-promotion partner on romosozumab (Evenity) for osteoporosis. UCB represents a potential strategic acquirer or commercial partner for Angitia given overlapping bone-disease commercial infrastructure outside the US.
  • Amgen: Amgen co-developed and markets Evenity (romosozumab), the first approved sclerostin-targeting antibody for postmenopausal osteoporosis. Romosozumab is the most direct competitive analog to Angitia's AGA2118 in mechanism and indication, though it targets only one of the two pathways AGA2118 engages.
  • Eli Lilly: Lilly markets Forteo (teriparatide) and Taltz in adjacent bone and inflammation indications, and is one of the dominant incumbent players in metabolic bone disease. Lilly represents the broad incumbent peer and potential strategic acquirer given the size of its bone franchise.
  • BridgeBio Pharma: BridgeBio is a clinical-stage rare disease biotech with multiple programs across genetic diseases. While not focused on musculoskeletal indications, BridgeBio is a structural peer in the clinical-stage rare disease and orphan drug space, particularly relevant for valuing Angitia's AGA2115 osteogenesis imperfecta program.

Others

  • Genmab: Genmab is a leader in bispecific antibody engineering with its DuoBody platform, used across multiple therapeutic areas. While not a direct competitor in musculoskeletal disease, Genmab is a technology-platform peer whose valuation and partnership economics inform the bispecific antibody space Angitia operates in.

Emerging players

  • Ascendis Pharma: Ascendis Pharma develops TransCon PTH (palopegteriparatide) for hypoparathyroidism and is exploring bone-related indications using its TransCon prodrug technology. The company is a peer in late-stage bone therapeutics with a similar clinical-stage, partnership-friendly profile.
  • Entera Bio: Entera Bio is developing oral PTH formulations (EB613) for osteoporosis and hypoparathyroidism. While mechanistically distinct from Angitia's bispecific antibodies, Entera is a clinical-stage peer targeting the same postmenopausal osteoporosis market with a differentiated route of administration.

Direct peers

  • Mereo BioPharma: Mereo is advancing setrusumab (anti-sclerostin) for osteogenesis imperfecta and other bone disorders, making it a direct competitor to Angitia's AGA2115 in the OI indication. Both companies are clinical-stage with a shared target biology in rare bone disease.
  • Ultragenyx Pharmaceutical: Ultragenyx is developing UX143 (setrusumab), an anti-sclerostin antibody for osteogenesis imperfecta — directly competing with Angitia's AGA2115 in the same rare bone disease indication and overlapping mechanism (sclerostin inhibition).
  • Radius Health: Radius developed and previously marketed Tymlos (abaloparatide), a parathyroid hormone analog for postmenopausal osteoporosis. Radius is a direct commercial-stage peer in osteoporosis therapeutics and a useful comparator for go-to-market economics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Angitia Biopharmaceuticals social profiles

Digital presence

Angitia Biopharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Angitia Biopharmaceuticals leadership team

Management profile

Number of profiles

Profiles2 records

Angitia Biopharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Angitia Biopharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Angitia Biopharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Angitia Biopharmaceuticals

What does Angitia Biopharmaceuticals do?

Angitia Biopharmaceuticals is a clinical-stage biotechnology company that discovers and develops biologic therapeutic candidates for serious musculoskeletal diseases. Its pipeline comprises three bispecific antibody drug candidates: AGA2118 for postmenopausal osteoporosis (Phase 2 ARTEMIS trial), AGA2115 for osteogenesis imperfecta (Phase 2 IDUN trial), and AGA111 for spinal fusion. The bispecific antibodies simultaneously target sclerostin and Dickkopf-1 (DKK1) proteins to overcome limitations of single-target bone therapies.

Is Angitia Biopharmaceuticals a public or private company?

Angitia Biopharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Angitia Biopharmaceuticals founded?

Angitia Biopharmaceuticals was founded in 2018. It employs 51 to 100 people.

Where is Angitia Biopharmaceuticals based?

Angitia Biopharmaceuticals is headquartered in Westlake Village, United States, in the North America region.

How does Angitia Biopharmaceuticals make money?

One revenue line is on record: biopharmaceutical Product Sales.

Who are Angitia Biopharmaceuticals's main competitors?

Broad incumbents on record are UCB, Amgen, Eli Lilly and BridgeBio Pharma. Genmab is listed as an others. Emerging players are Ascendis Pharma and Entera Bio. Direct peers are Mereo BioPharma, Ultragenyx Pharmaceutical and Radius Health.

Does Angitia Biopharmaceuticals have an API?

No public API is recorded for Angitia Biopharmaceuticals.

What industry is Angitia Biopharmaceuticals in?

Angitia Biopharmaceuticals's product category is Musculoskeletal Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterAngitia reshapes bone pipeline after ending Phase III trialAngitia Biopharmaceuticals has terminated a Phase III trial of AGA111, its most advanced clinical-stage asset, for patients with degenerative disc disease undergoing lumbar interbody fusion. The termination occurred approximately five months after the privately-held bone disease specialist raised $130 million in series D financing. The halt was posted to ClinicalTrials.gov this week.Longevity.TechnologyAngitia Bio lands $130m to advance human trials of musculoskeletal health drugsUS biotech Angitia Biopharmaceuticals has secured $130 million in Series D financing co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners to advance clinical-stage programs for musculoskeletal diseases. The funding will fuel development of the company's bispecific antibody AGA2118 for postmenopausal osteoporosis, which recently completed enrollment of 379 women in a Phase 2 trial with topline results expected in 2027. Angitia's approach targets both sclerostin and Dickkopf-1 proteins simultaneously to overcome limitations of single-target therapies for bone loss conditions affecting hundreds of millions of women worldwide.FierceBiotechAngitia raises $130M to challenge Amgen with bone-building bispecificsAngitia Biopharmaceuticals raised $130 million in Series D financing, co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners, to advance three bone disease candidates into deeper clinical trials. The pipeline includes AGA111 in a Phase 3 spinal fusion trial, and two bispecific antibodies (AGA2118 and AGA2115) targeting sclerostin and DKK1 for osteoporosis and osteogenesis imperfecta, with Phase 2 osteoporosis data expected next year. The dual-mechanism approach differentiates Angitia from competitors targeting the bone disease space, including Amgen's approved osteoporosis drug Evenity.Venture Capital Access OnlineAngitia Biopharmaceuticals Announces $130 Million Series D FinancingAngitia Biopharmaceuticals announced the closing of a $130 million Series D financing round co-led by Frazier Life Sciences and Venrock Healthcare Capital Partners, with participation from multiple new and existing investors. Proceeds will support the continued clinical development of the company's pipeline candidates including AGA2118, AGA2115, and AGA111 for serious musculoskeletal diseases. Kevin Li, M.D., a Partner at Frazier Life Sciences, will join the company's Board of Directors in connection with the financing.GlobeNewswireAngitia Biopharmaceuticals Announces Dosing of First Participant in Phase 2 IDUN Trial of AGA2115 for the Treatment of Osteogenesis ImperfectaAngitia Biopharmaceuticals announced the first patient dosing in its Phase 2 IDUN trial of AGA2115 for osteogenesis imperfecta. The trial will enroll about 80 adults with Type I, III, or IV OI, with primary analysis at Month 12. The company expects to replicate bone quality improvements seen in preclinical studies.GlobeNewswireAngitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of OsteoporosisAngitia Biopharmaceuticals completed enrollment in the Phase 2 ARTEMIS trial evaluating AGA2118, a bispecific antibody for osteoporosis, in 379 postmenopausal women. The trial's primary endpoint is lumbar spine BMD change at Month 12, with topline data expected in 2027.GlobeNewswireAngitia Biopharmaceuticals Presents First-in-Human Data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025Angitia Biopharmaceuticals presented first-in-human data on AGA2115 for osteogenesis imperfecta at ASBMR 2025, showing dose-dependent increases in bone mineral density. In a Phase 1 trial, the bispecific antibody increased lumbar spine BMD by 14.4% and total hip BMD by 3.6% at the highest dose. The company plans a Phase 2 study in adult OI patients.GlobeNewswireAngitia Biopharmaceuticals to Present Data on AGA2115 for Osteogenesis Imperfecta at ASBMR 2025Angitia Biopharmaceuticals will present data on AGA2115 for osteogenesis imperfecta at ASBMR 2025 in Seattle, with two oral presentations and three posters. The bispecific antibody targets DKK1 and sclerostin, and has received orphan and rare pediatric disease designations. A Phase 2 study in adult OI patients is planned.GlobeNewswireAngitia Biopharmaceuticals Announces Topline Results from First in Human Study of AGA2115, A Bispecific Antibody for the Treatment of Osteogenesis ImperfectaAngitia Biopharmaceuticals announced top-line results from its Phase 1 study of AGA2115, a bispecific antibody for osteogenesis imperfecta, showing favorable safety and robust increases in bone mineral density. The EMA granted Orphan Drug Designation to AGA2115, and the company plans a Phase 2 study in adult OI patients.The Manila TimesAngitia Biopharmaceuticals Announces Topline Results from First in Human Study of AGA2115, A Bispecific Antibody for the Treatment of Osteogenesis ImperfectaAngitia Biopharmaceuticals announced top-line results from its Phase 1 study of AGA2115, a bispecific antibody for osteogenesis imperfecta, showing favorable safety and increased bone mineral density. The EMA granted Orphan Drug Designation to AGA2115, and the company plans a Phase 2 study in adult patients with pediatric studies to follow.